Cargando…

Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center

Background: In the last decades, long-term outcomes of breast cancer (BC) patients have improved, raising new survivorship issues, including fertility preservation and safety of pregnancy after BC. This study assesses evolution in patterns of fertility discussion/preservation over time and reports p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dieci, Maria Vittoria, Ghiotto, Cristina, Barbieri, Caterina, Griguolo, Gaia, Saccardi, Carlo, Gangemi, Michele, Pluchinotta, Alfonso, Di Liso, Elisabetta, Giorgi, Carlo Alberto, Giarratano, Tommaso, Tasca, Giulia, Vernaci, Grazia, Faggioni, Giovanni, Conte, Pierfranco, Guarneri, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482901/ https://www.ncbi.nlm.nih.gov/pubmed/29963941 http://dx.doi.org/10.1089/jwh.2018.6986

Ejemplares similares

Immune characterization of breast cancer metastases: prognostic implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2018)

Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
por: Urso, Loredana, et al.
Publicado: (2021)

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
por: Miglietta, Federica, et al.
Publicado: (2022)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases
por: Di Liso, Elisabetta, et al.
Publicado: (2020)

Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
por: Bottosso, Michele, et al.
Publicado: (2023)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review
por: Vernaci, Grazia Maria, et al.
Publicado: (2021)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center
por: Tasca, Giulia, et al.
Publicado: (2020)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary
por: Giarratano, Tommaso, et al.
Publicado: (2018)

A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
por: Griguolo, Gaia, et al.
Publicado: (2022)

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
por: Guarneri, V., et al.
Publicado: (2022)

The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
por: Zarrilli, Giovanni, et al.
Publicado: (2020)

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
por: Miglietta, F., et al.
Publicado: (2022)

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]
por: Miglietta, F., et al.
Publicado: (2022)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
por: Ratosa, Ivica, et al.
Publicado: (2022)

Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review
por: Mantiero, Mara, et al.
Publicado: (2018)

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
por: Carbognin, Luisa, et al.
Publicado: (2020)

Cancer Control in Central and Eastern Europe
por: La Vecchia, Carlo, et al.
Publicado: (2016)

Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
por: Massa, Davide, et al.
Publicado: (2022)

An overview of immune checkpoint inhibitors in breast cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

GD2 expression in breast cancer
por: Orsi, Giulia, et al.
Publicado: (2017)

Fertility sparing surgery in young women affected by endometrial stromal sarcoma: an oncologic dilemma or a reliable option? review of literature starting from a peculiar case
por: Noventa, Marco, et al.
Publicado: (2014)

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment
por: Frega, Stefano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5d4gbng06cj31p99usv7jdpj2k